Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866132 · ClinicalTrials.gov registry record · NA
Response to an Investigational Device in Patients With Restless Legs Syndrome
A NA study of Restless Legs Syndrome, sponsored by Noctrix Health.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06866132: Active NA study of Restless Legs Syndrome, sponsored by Noctrix Health.
NCT06866132 is a NA study of Restless Legs Syndrome that is active but no longer recruiting, run by Noctrix Health. The registered enrollment target is 20 participants, below the 95-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06866132, a NA study of Restless Legs Syndrome, is active but no longer recruiting, sponsored by Noctrix Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
Primary Outcome
International Restless Legs Syndrome Study Group (IRLS) Rating Scale Score is a participant-rated questionnaire that rates RLS severity from 0-40, where 40 is the most severe. The mean change is assessed from study entry to Week 10.
Conditions Studied
Interventions
- DEVICE Investigational Noninvasive Neuromodulation Device
Study Locations (1)
California
- Noctrix Health Headquarters - Pleasanton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What the registry record for NCT06866132 still lists
NCT06866132 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 95-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Investigational Noninvasive Neuromodulation Device is the first listed.
NCT06866132 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06866132 about?
NCT06866132 is a clinical study titled "Response to an Investigational Device in Patients With Restless Legs Syndrome". This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
What is the current status of trial NCT06866132?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-03-11. Estimated completion is 2025-09-30.
What conditions does trial NCT06866132 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT06866132?
The interventions under investigation include: Investigational Noninvasive Neuromodulation Device (DEVICE).
Who is sponsoring clinical trial NCT06866132?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866132 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06866132's enrollment target sits among peer trials
20 14th of 14 higher than 1 of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction
COMPLETED · NA
-
A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome
COMPLETED · NA
-
Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
COMPLETED · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI